Fig. 6.

Prognostic role of AR in different breast cancer patients. a Overall patients (n = 103), 2 cases (2.78%,2/72) in the AR + group vs 9 cases (29.03%,9/31) in the AR- group experienced disease progression. b TNBC patients(n = 16), no patient (0/2) in the AR + group versus 4 cases (28.57%,4/14) in the AR– group experienced disease progression. c HER2 overexpression subtype patients(n = 32), 1 case (4.17%,1/24) in the AR + group versus 4 cases (50%,4/8) in the AR- group experienced disease progression. d Luminal A subtype patients(n = 31), 1 case (3.85%,1/26) in the AR + group versus no patient (0/5) in the AR– group experienced disease progression. e Luminal B subtype patients(n = 24), no patient (0/20) in the AR + group versus 1 case (25%,1/4) in the AR– group experienced disease progression. TNBC, triple negative breast cancer; HER2, human epidermal growth factor receptor 2; AR, androgen receptor; PFS, progression-free survival; * indicates p < 0.05